Evidence map›Paper›PMID 39253139›Full record

ReviewHeliyon2024

Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential.

Xi Zhao, Yunong Ma, Jiayang Luo, Kexin Xu, Peilin Tian, Cuixia Lu, Jiaxing Song

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. A Review onPlants (Basel, Switzerland) · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xi ZhaoMedical Scientific Research Center, Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
Yunong MaMedical Scientific Research Center, Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
Jiayang LuoMedical Scientific Research Center, Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
Kexin XuMedical Scientific Research Center, Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
Peilin TianMedical Scientific Research Center, Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
Cuixia LuMedical Scientific Research Center, Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
Jiaxing SongChina Medical College of Guangxi University, Guangxi University, Nanning, 530004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The WNT/β-catenin signaling pathway plays crucial roles in tumorigenesis and relapse, metastasis, drug resistance, and tumor stemness maintenance. In most tumors, the WNT/β-catenin signaling pathway is often aberrantly activated. The therapeutic usefulness of inhibition of WNT/β-catenin signaling has been reported to improve the efficiency of different cancer treatments and this inhibition of signaling has been carried out using different methods including pharmacological agents, short interfering RNA (siRNA), and antibodies. Here, we review the WNT-inhibitory effects of some FDA-approved drugs and natural products in cancer treatment and focus on recent progress of the WNT signaling inhibitors in improving the efficiency of chemotherapy, immunotherapy, gene therapy, and physical therapy. We also classified these FDA-approved drugs and natural products according to their structure and physicochemical properties, and introduced briefly their potential mechanisms of inhibiting the WNT signaling pathway. The review provides a comprehensive understanding of inhibitors of WNT/β-catenin pathway in various cancer therapeutics. This will benefit novel WNT inhibitor development and optimal clinical use of WNT signaling-related drugs in synergistic cancer therapy.

Indexed as

Drug developmentDrug discoveryDrug targetMedicinal researchWNT/β-catenin

Identifiers

PMID39253139
PMCPMC11381626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.